<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03668509</url>
  </required_header>
  <id_info>
    <org_study_id>SHR1459-101</org_study_id>
    <nct_id>NCT03668509</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and PK/PD of SHR1459 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR1459, in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a phase I, single-center, double-blind, randomized, placebo-controlled study to
      assess the safety, tolerability and pharmacokinetics/pharmacodynamics of the investigational
      medicinal product in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study originally planned to enroll 3 cohorts of 10 subjects each (N=30).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single oral doses of SHR1459 determined by adverse events</measure>
    <time_frame>within 4 days after single dose</time_frame>
    <description>Frequency and severity of AEs and serious AEs</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral adminstration of SHR1459, dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral adminstration of SHR1459, dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral adminstration of SHR1459, dose 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR1459</intervention_name>
    <description>oral adminstration, single dose</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, of any ethnic origin, age ≥18 and ≤45 years of age;

          -  BMI ≥19 and ≤26 kg/m2; Men's weight≥ 50kg, Women's weight ≥ 45kg;

          -  Medical history without major pathology and determined to be in good health with no
             clinically significant findings as assessed by the Investigator; all clinical tests of
             blood, urine, ECG and X-ray are within the normal range or show no clinically relevant
             deviations as judged by the Investigator;

          -  There is no birth plan during the trial and within 1 month after the completion of the
             trial, and the subject must agree to use one of the effective contraceptive methods;

          -  Able to comprehend and abide by the study restrictions, and willing to sign an
             Informed Consent Form (ICF)

        Exclusion Criteria:

          -  Has a history of significant hypersensitivity, intolerance, or allergy to any drug
             compound, food, or other substance, unless approved by the Investigator;

          -  Has a history of malignant or lymphoproliferative disorders;

          -  Has a history of bleeding tendency or coagulopathy (eg, uncontrolled autoimmune
             hemolysis and thrombocytopenic purpura, severe hematopoietic defects, gastrointestinal
             bleeding), or recent bleeding events;

          -  Has a history of stroke or intracranial hemorrhage within 6 months prior to screening;

          -  Has any surgery performed within 3 months prior to screening, or during the study
             period and within 1 month after the end of the study;

          -  Has a significant history or clinical manifestation of any metabolic, allergic,
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,
             gastrointestinal, neurological, respiratory, endocrine, immune suppressive/defective,
             or psychiatric disorder as determined by the Investigator;

          -  Has diseases affecting drug absorption, distribution, metabolism, and excretion (eg,
             gastrointestinal dysfunction, peptic ulcer, gastrointestinal surgery, etc);

          -  Has active tuberculosis by clinical symptoms, signs, laboratory tests, or X-ray
             examinations;

          -  Has infections including acute and chronic infections, local infections such as
             sepsis, abscesses, and opportunistic infections that were clinically significant by
             the investigator in the 3 months prior to screening;

          -  Has blood donation and donated ≥400 mL within 3 months before screening ; or received
             any blood product infusion; or received plasma exchange or blood cell clearance
             treatment;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hua Zhang, MD</last_name>
    <phone>+86-512-67780040</phone>
    <email>sdfyy8040@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xu qian, M.D. Ph.D</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qian Xu, Ph.D</last_name>
      <phone>+86-18721043271</phone>
      <email>xuqian@hrglobe.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>September 11, 2018</last_update_submitted>
  <last_update_submitted_qc>September 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SHR1459</keyword>
  <keyword>Phase 1</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

